Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL27570167 | 0.80 | TDP1 (0.52) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL450290 | 0.78 | TDP1 (0.50) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL27342954 | 0.77 | CA12 (0.61) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL2061293 | 0.77 | TDP1 (0.48) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL1838258 | 0.77 | CA12 (0.69) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL28230816 | 0.77 | CA12 (0.69) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL10394593 | 0.77 | CA12 (0.69) | TDP1CA12CA1CA2GLA | |
| SCHEMBL4487168 | 0.76 | — | — | |
| Phenol SCHEMBL10905158 | 0.75 | TDP1 (0.46) | TDP1CA12CA1CA2GLA | |
| Phenol SCHEMBL28098271 | 0.75 | CA12 (0.58) | TDP1CA12CA1CA2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | TDP1 69/4885CA12 3985/4885CA1 4446/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | TDP1 67/4885CA12 4014/4885CA1 4599/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | TDP1 505/4885CA12 2998/4885CA1 1587/4885 |
| US-20060142266-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | TDP1 67/4885CA12 4014/4885CA1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.